Calamos Advisors LLC Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Calamos Advisors LLC cut its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 62.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,995 shares of the company's stock after selling 16,836 shares during the quarter. Calamos Advisors LLC's holdings in Vaxcyte were worth $818,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Janus Henderson Group PLC boosted its holdings in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after buying an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. boosted its position in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after purchasing an additional 485,436 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Vaxcyte by 47.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock worth $148,075,000 after acquiring an additional 419,600 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Vaxcyte in the third quarter valued at $41,114,000. Finally, Franklin Resources Inc. raised its stake in shares of Vaxcyte by 13.2% during the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after purchasing an additional 324,560 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent analyst reports. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $145.71.

Vaxcyte Stock Down 1.8 %

Shares of NASDAQ:PCVX traded down $1.59 during trading on Friday, hitting $87.42. The stock had a trading volume of 681,501 shares, compared to its average volume of 1,213,280. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The company has a market capitalization of $10.90 billion, a PE ratio of -19.00 and a beta of 0.98. The firm's fifty day moving average is $87.04 and its 200 day moving average is $94.47.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares of the company's stock, valued at $41,630,327.45. This trade represents a 3.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,616 shares of company stock valued at $6,095,681 in the last quarter. 3.10% of the stock is owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.